{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:57:51Z","timestamp":1781585871336,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ijcard.2024.132216","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T23:09:35Z","timestamp":1717024175000},"page":"132216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["An association between Dasatinib, elevated left atrial pressure and pleural effusion"],"prefix":"10.1016","volume":"410","author":[{"given":"Sean","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diva","family":"Baggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie","family":"Porch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitesh","family":"Nerlekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Shortt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2024.132216_bb0005","first-page":"37","article-title":"Gleevec: the breakthrough in cancer treatment","volume":"1","author":"Pray","year":"2008","journal-title":"Nat. Educ."},{"key":"10.1016\/j.ijcard.2024.132216_bb0010","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.132216_bb0015","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib versus Imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2024.132216_bb0020","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ijcard.2024.132216_bb0025","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quintas-Cardama","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2024.132216_bb0030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ijcard.2024.132216_bb0035","series-title":"National Cancer Institute: Common Terminology Criteria for Adverse Events Version 5.0, Bethesda, MD","author":"National Cancer Institute","year":"2017"},{"key":"10.1016\/j.ijcard.2024.132216_bb0040","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/imj.15517","article-title":"Prediction of cardiovascular events in patients with chronic myeloid leukaemia using baseline risk factors and coronary artery calcium scoring","volume":"51","author":"Baggio","year":"2021","journal-title":"Intern. Med. J."},{"issue":"Suppl. 2","key":"10.1016\/j.ijcard.2024.132216_bb0045","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imj.13716","article-title":"Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors","volume":"48","author":"Ross","year":"2018","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.ijcard.2024.132216_bb0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3324\/haematol.2018.188987","article-title":"Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia","volume":"104","author":"Hughes","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ijcard.2024.132216_bb0055","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/bloodadvances.2016003889","article-title":"The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia","volume":"1","author":"Fox","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.ijcard.2024.132216_bb0060","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treted with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ijcard.2024.132216_bb0065","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.24734","article-title":"Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion","volume":"116","author":"Porkka","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ijcard.2024.132216_bb0070","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00279-2020","article-title":"Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors","volume":"56","author":"Weatherald","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijcard.2024.132216_bb0075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacc.2003.07.046","article-title":"Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis","volume":"43","author":"Hogg","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2024.132216_bb0080","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.clml.2015.09.008","article-title":"Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on National Comprehensive Network Treatment Guidelines","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ijcard.2024.132216_bb0085","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series","volume":"176","author":"Bergeron","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijcard.2024.132216_bb0090","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1517\/14740331003742935","article-title":"Pleural\/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development","volume":"9","author":"Breccia","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ijcard.2024.132216_bb0095","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1248\/bpb.b21-00270","article-title":"cAMP signaling pathway prevents dasatinib-induced vascular hyperpermeability","volume":"44","author":"Aoyama","year":"2021","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ijcard.2024.132216_bb0100","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3389\/fphys.2018.00537","article-title":"Rho-kinase inhibition ameliorates Dasatinib-induced endothelial dysfunction and pulmonary hypertension","volume":"9","author":"Fazakas","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ijcard.2024.132216_bb0105","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01096-2017","article-title":"Dasatinib increases endothelial permeability leading to pleural effusion","volume":"51","author":"Phan","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijcard.2024.132216_bb0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/MAJ.0b013e3181a3936f","article-title":"Pericardial and pleural effusions in congestive heart failure-anatomical, pathophysiologic, and clinical considerations","volume":"338","author":"Natanzon","year":"2009","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ijcard.2024.132216_bb0115","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/cam4.3588","article-title":"Change of right ventricular systolic pressure can indicate dasatinib-induced pulmonary arterial hypertension in chronic myeloid leukemia","volume":"10","author":"Lee","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.ijcard.2024.132216_bb0120","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.16971","article-title":"A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia","volume":"191","author":"Smith","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ijcard.2024.132216_bb0125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/asheducation-2017.1.110","article-title":"Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy","volume":"1","author":"Barber","year":"2017","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324008386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324008386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T22:38:05Z","timestamp":1719614285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527324008386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":25,"alternative-id":["S0167527324008386"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132216","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An association between Dasatinib, elevated left atrial pressure and pleural effusion","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"132216"}}